DanDrit Biotech USA

DanDrit Biotech USA is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer.

DanDrit is a biotechnology company focusing on VIVA, a Phase III clinical trial for our lead candidate MCV. MCV is an adjuvant immunotherapy that is designed to prevent colon cancer recurrence after standard of care surgery and chemotherapy. MCV, a dendritic cell cancer vaccine, can be used in several solid tumors either as a standalone adjuvant therapy or in combination with checkpoint inhibitors. Our expertise in producing dendritic cells from a patient's blood is combined with conventional production methods with a goal of making new and advanced vaccines for cancer patients.